NCT00595140

Acute Application of Pegvisomant and Octreotide in Acromegaly

The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Ludwig-Maximilians - University of Munich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.

Conditions

• Acromegaly

Interventions

Type	Name	Description
DRUG	pegvisomant	growth hormone receptor antagonist pegvisomant in patients´ individual dose
DRUG	combination with somatostatin analogue octreotide	s.c., 100µg, one time
DRUG	combination with dopamine agonist cabergoline	oral, 0.5mg, one time

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-03-01
• Completion: 2008-03-01
• First posted: 2008-01-16
• Last updated: 2008-04-01

Locations

1 site across 1 country: Germany